Literature DB >> 16036377

Regulatory T cells in the control of autoimmune diabetes: the case of the NOD mouse.

Lucienne Chatenoud1, Jean-François Bach.   

Abstract

Over the last few years, there has been a revival of the concept of suppressor/regulatory T cells being central players in the control of various immune responses, including autoimmune responses and immune response to transplants, tumors, and infectious agents. It appears that regulatory T cells are diverse in their phenotypes, antigen specificity, and modes of action. Here we summarize studies from various groups, including our own, demonstrating that specialized subsets of regulatory T cells are pivotal in the control of autoimmune diabetes as well shown by the compelling evidence accumulated using the non-obese diabetic (NOD) mouse model. We also provide a discussion of the evidence showing that some biological products (such as CD3-specific monoclonal antibodies) are representatives of a new category of immunotherapeutic agents endowed with unique capacities to promote immunological tolerance (an antigen-specific unresponsiveness in the absence of long-term generalized immunosuppression) through their ability to induce immunoregulatory T cells.

Entities:  

Mesh:

Year:  2005        PMID: 16036377     DOI: 10.1080/08830180590934994

Source DB:  PubMed          Journal:  Int Rev Immunol        ISSN: 0883-0185            Impact factor:   5.311


  12 in total

1.  Oral Administration of OKT3 MAb to Patients with NASH, Promotes Regulatory T-cell Induction, and Alleviates Insulin Resistance: Results of a Phase IIa Blinded Placebo-Controlled Trial.

Authors:  Gadi Lalazar; Meir Mizrahi; Ilit Turgeman; Tomer Adar; Ami Ben Ya'acov; Yehudit Shabat; Assy Nimer; Nila Hemed; Lidya Zolotarovya; Yoav Lichtenstein; Nadya Lisovoder; Sarit Samira; Itamar Shalit; Ronald Ellis; Yaron Ilan
Journal:  J Clin Immunol       Date:  2015-04-17       Impact factor: 8.317

2.  Induction of regulatory T cells decreases adipose inflammation and alleviates insulin resistance in ob/ob mice.

Authors:  Yaron Ilan; Ruth Maron; Ann-Marcia Tukpah; Tatiani Uceli Maioli; Gopal Murugaiyan; Kaiyong Yang; Henry Yim Wu; Howard L Weiner
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-05       Impact factor: 11.205

Review 3.  Cytokines in autoimmunity: role in induction, regulation, and treatment.

Authors:  Kamal D Moudgil; Divaker Choubey
Journal:  J Interferon Cytokine Res       Date:  2011-09-23       Impact factor: 2.607

Review 4.  Immune intervention in type 1 diabetes.

Authors:  Aaron W Michels; George S Eisenbarth
Journal:  Semin Immunol       Date:  2011-08-17       Impact factor: 11.130

5.  Genetic and Pharmacologic Models for Type 1 Diabetes.

Authors:  Edward H Leiter; Andrew Schile
Journal:  Curr Protoc Mouse Biol       Date:  2013-03-01

6.  Diabetes in non-obese diabetic mice is not associated with quantitative changes in CD4+ CD25+ Foxp3+ regulatory T cells.

Authors:  Richard J Mellanby; David Thomas; Jenny M Phillips; Anne Cooke
Journal:  Immunology       Date:  2007-05       Impact factor: 7.397

7.  Design of targeted B cell killing agents.

Authors:  Alexey V Stepanov; Alexey A Belogurov; Natalia A Ponomarenko; Oleg A Stremovskiy; Leonid V Kozlov; Anna M Bichucher; Sergey E Dmitriev; Ivan V Smirnov; Olga G Shamborant; Dmitry S Balabashin; Lidia P Sashchenko; Alexander G Tonevitsky; Alain Friboulet; Alexander G Gabibov; Sergey M Deyev
Journal:  PLoS One       Date:  2011-06-06       Impact factor: 3.240

Review 8.  Sjögren's syndrome: studying the disease in mice.

Authors:  Nicolas Delaleu; Cuong Q Nguyen; Ammon B Peck; Roland Jonsson
Journal:  Arthritis Res Ther       Date:  2011-06-13       Impact factor: 5.156

9.  Human cord blood stem cell-modulated regulatory T lymphocytes reverse the autoimmune-caused type 1 diabetes in nonobese diabetic (NOD) mice.

Authors:  Yong Zhao; Brian Lin; Robert Darflinger; Yongkang Zhang; Mark J Holterman; Randal A Skidgel
Journal:  PLoS One       Date:  2009-01-19       Impact factor: 3.240

10.  Prevention or early cure of type 1 diabetes by intranasal administration of gliadin in NOD mice.

Authors:  David P Funda; Petra Fundova; Axel Kornerup Hansen; Karsten Buschard
Journal:  PLoS One       Date:  2014-04-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.